Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9060/2024, 20 February 2024)
| Date | 20 February 2024 |
|---|---|
| Court | CFI |
| Division | Paris (FR) Central Division - Seat |
| Type of action | Generic application |
| Case number(s) | UPC_CFI_454/2023 |
| Registry reference | App_8391/2024 · ORD_9060/2024 · UPC_CFI_454/2023 |
| Parties | Roche Diabetes Care GmbH |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 20 February 2024 (UPC_CFI_454/2023), the judge-rapporteur of the Paris Central Division, in the revocation action against EP 2 196 231 brought by Tandem Diabetes Care, Inc. and Tandem Diabetes Care Europe B.V. against Roche Diabetes Care GmbH, rejected Roche’s request to extend the time limit for its Defence to revocation on the ground that a preliminary objection to jurisdiction was pending. The order confirms that extensions remain exceptional and that a preliminary objection does not, of itself, suspend the time limit for the Defence.
Question
Do a pending preliminary objection, the cost of possibly wasted pleadings and the risk of a stay of parallel proceedings justify extending the time limit for the Defence (Rule 9.3 RoP) or a decision otherwise under Rule 19.6 RoP?
Decision
The judge-rapporteur recalled that Rule 9 RoP confers a discretion to be exercised in line with proportionality, flexibility, fairness and equity (paragraphs 8 and 9), and that time limits serve speed, a fair trial and legal certainty (paragraphs 10 to 15). Extensions must be granted with caution and only in justified exceptional cases, the requesting party having to show that compliance is objectively impossible or very difficult (paragraphs 16 and 17). Roche alleged no such difficulty, only the risk of wasted pleadings should the objection succeed (paragraph 18), the risk of a stay of the non-infringement action was irrelevant (paragraph 19). Under Rule 19.6 RoP the time limit for the Defence runs despite the preliminary objection unless decided otherwise, which requires the same justification (paragraphs 20 to 23).
Key points for practice
- Practical point: a party raising a preliminary objection should prepare its Defence within the normal time limit unless it can show an objective difficulty in meeting it.
Provisions applied
- Rules of Procedure
- Rules 9.3, 9.4, 19.6, 23, 48, 76.3 and 333
- Case law cited
- ITCiCo Spain, Paris Central Division, 9 February 2024, Paris Central Division, order of 10 November 2023, UPC_CFI_255/2023
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC), Court fees and costs (UPC).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantRoche Diabetes Care GmbH14 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Generic application
- Outcome (Dhenne Avocats summary)
- Le juge rapporteur rejette la prorogation du délai de défense à l'action en nullité : l'exception préliminaire pendante ne suffit pas, faute de difficulté objective démontrée à respecter le délai.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 196 231mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Bayerische Motoren Werke v ITCiCo Spain (CFI, 9 February 2024) cited in this record
- Genevant Sciences v Moderna (CFI, 13 August 2025) cites this decision
- Meril Life Sciences v Edwards Lifesciences (CFI, 17 September 2024) cites this decision
- Tandem Diabetes Care v Roche Diabetes Care (CFI, 27 June 2024) cites this decision
- Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9062/2024, 20 February 2024) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 196 231System for ambulatory drug infusion comprising a filling apparatus for flexible containers recorded proprietor: F Hoffmann La Roche AG et Roche Diagnostics GmbH | Mentioned in the analysis (role not qualified) Also mentioned in 9 other decision(s): Tandem Diabetes Care Europe v Roche Diabetes Care (CFI, 18 December 20 · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 3 July 2025) · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 5 June 2025) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 9 September 2024) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 26 July 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 27 June 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 10 May 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9062/2024, 20 Feb | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.